UA98665C2 - Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method - Google Patents

Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method

Info

Publication number
UA98665C2
UA98665C2 UAA201003470A UAA201003470A UA98665C2 UA 98665 C2 UA98665 C2 UA 98665C2 UA A201003470 A UAA201003470 A UA A201003470A UA A201003470 A UAA201003470 A UA A201003470A UA 98665 C2 UA98665 C2 UA 98665C2
Authority
UA
Ukraine
Prior art keywords
medicinal preparation
treatment method
malignant cells
action against
against malignant
Prior art date
Application number
UAA201003470A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Геннадий Васильевич Мазильников
Аркадий Петрович Шиманский
Юрий Анатольевич Лиходед
Стефания Стефановна Мельник
Original Assignee
Геннадий Васильевич Мазильников
Аркадий Петрович Шиманский
Лиходид Юрий Анатольевич
Стефания Стефановна Мельник
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Геннадий Васильевич Мазильников, Аркадий Петрович Шиманский, Лиходид Юрий Анатольевич, Стефания Стефановна Мельник filed Critical Геннадий Васильевич Мазильников
Priority to UAA201003470A priority Critical patent/UA98665C2/en
Priority to PCT/UA2010/000014 priority patent/WO2011119125A1/en
Publication of UA98665C2 publication Critical patent/UA98665C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

The invention relates to medicine, in particular to oncology, and concerns a medicinal preparation comprising lithium oxalate, dimethylxanthine and fluorouracil, and to a method for the treatment of malignant tumours.
UAA201003470A 2010-03-25 2010-03-25 Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method UA98665C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
UAA201003470A UA98665C2 (en) 2010-03-25 2010-03-25 Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method
PCT/UA2010/000014 WO2011119125A1 (en) 2010-03-25 2010-03-26 Use of lithium oxalate in production of a therapeutic preparation with anti-tumour activity in relation to malignant cells, a therapeutic preparation based thereon and a method of treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAA201003470A UA98665C2 (en) 2010-03-25 2010-03-25 Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method

Publications (1)

Publication Number Publication Date
UA98665C2 true UA98665C2 (en) 2012-06-11

Family

ID=44673472

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003470A UA98665C2 (en) 2010-03-25 2010-03-25 Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method

Country Status (2)

Country Link
UA (1) UA98665C2 (en)
WO (1) WO2011119125A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074055A1 (en) * 2011-11-16 2013-05-23 ШИМАНСКИЙ, Аркадий Петрович Method for restoring and rejuvenating the human body and a pharmaceutical composition for implementation thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133317A (en) * 1995-11-15 2000-10-17 Hart; Francis J. Oxalic acid or oxalate composition and method of treatment
AU2003270202A1 (en) * 2002-09-17 2004-04-08 Centre National De La Recherche Scientifique Pharmaceutical compositions increasing camp useful for the treatment of cancers
BRPI0511780A (en) * 2004-06-03 2008-01-15 Hoffmann La Roche oxoliplatin treatment and an egrf inhibitor
ZA200701578B (en) * 2004-07-23 2008-09-25 Om Pharma Combination anticancer therapy and pharmaceutical compositions therefore
CN101657203B (en) * 2007-03-02 2012-09-05 卧龙岗大学 Compositions and methods for delivery of anti-cancer agents

Also Published As

Publication number Publication date
WO2011119125A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
GB201106743D0 (en) Novel compounds
PL2807159T3 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing them for the treatment of cancer
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
MX364229B (en) COMPOSITIONS and METHODS FOR TREATING CARDIOVASCULAR DISEASES.
MX366804B (en) R-spondin translocations and methods using the same.
EP2563426A4 (en) High shear application in medical therapy
PH12015501088A1 (en) Dimeric compounds
IL207310A0 (en) Vaccine compositions
MX2014010713A (en) Procaspase 3 activation by combination therapy.
MX359209B (en) Procaspase combination therapy for glioblastoma.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
EP2963125A4 (en) Method for assaying microrna, cancer therapeutic agent, and medicinal composition containing same for cancer therapy
WO2014083019A3 (en) Agent for modulating the dissemination of cancer cells, product comprising said agent, and use of said agent in the treatment and/or prevention of cancer
UA98665C2 (en) Medicinal preparation exhibiting antineoplastic action against malignant cells and treatment method
GB2528604A (en) Modulation of asymmetric proliferation
UA98666C2 (en) Medicinal preparation based on oxalic acid exhibiting antineoplastic action against malignant cells, and treatment method
MX2013012551A (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
HK1204282A1 (en) Drug composition, and soft capsule containing same
MX350868B (en) MEDICAMENTS and METHODS FOR TREATING CANCER.
TN2013000404A1 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
UA46888U (en) Method for treating locally advanced forms of breast cancer
UA60887U (en) Method for complex treatment of locally advanced breast cancer
UA55887U (en) Method for diagnostics of risk of progression of hyperplasia of endometrium to pre-cancer and cancer of endometrium
UA77442U (en) Method for treating chronic periodontitis
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists